By a News Reporter-Staff News Editor at Clinical Trials Week -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted [10 yes, 3 no] that ... Pharmaceutical & Medical Packaging News, 1 day ago
Boehringer Ingelheim Pharmaceuticals, Inc. Announces U.S. Filing For The Fixed-Dose Combination Tiotropium Plus Olodaterol For Patients With COPD
RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ --Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and ...BioSpace, 3 days ago Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD TickerTech.com, 3 days ago
on your WebpageAdd Widget >Get your members hooked!